Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “CD19-chimeric Antigen Receptor T Cells”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Early research (Phase 1)Not Yet RecruitingNCT07113496
What this trial is testing

RN1201injection for Relapsed/Refractory CD19+/BCMA+ Hematologic Malignancies

Who this might be right for
Relapsed or Refractory B-cell Hematologic MalignanciesB-cell Acute Lymphoblastic Leukemia (B-ALL)Multiple Myeloma (MM)+3 more
The First Affiliated Hospital with Nanjing Medical University 27
Testing effectiveness (Phase 2)Not Yet RecruitingNCT05432882
What this trial is testing

CD19/22 Bi-specific CAR-T Cell Therapy

Who this might be right for
B Cell Malignancies
Shenzhen Geno-Immune Medical Institute 60
Early research (Phase 1)Study completedNCT03919526
What this trial is testing

Anti-CD19/CD22 Bispecific Chimeric Antigen Receptor（CAR)-T Cell Therapy for Measurable Residual Disease(MRD) Positive ALL

Who this might be right for
MRD-positiveAcute Lymphoblastic Leukemia
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine 19
Testing effectiveness (Phase 2)Active Not RecruitingNCT04889716
What this trial is testing

CAR-T Followed by Bispecific Antibodies

Who this might be right for
Large B-cell LymphomaDLBCL - Diffuse Large B Cell Lymphoma
Abramson Cancer Center at Penn Medicine 23
Early research (Phase 1)UnknownNCT03271515
What this trial is testing

Immunotherapy With Bispecific CAR-T Cells for B-Cell Lymphoma, ALL and CLL

Who this might be right for
LeukemiaLymphoma
Beijing Doing Biomedical Co., Ltd. 20
Early research (Phase 1)UnknownNCT02456350
What this trial is testing

Anti-CD19 Chimeric Antigen Receptor (CAR)-Transduced T Cell Therapy for Patients With B Cell Malignancies

Who this might be right for
Chronic Lymphocytic LeukemiaAcute Lymphocytic LeukemiaLymphoma
Shenzhen Second People's Hospital 36
Early research (Phase 1)Active Not RecruitingNCT03330691
What this trial is testing

A Feasibility and Safety Study of Dual Specificity CD19 and CD22 CAR-T Cell Immunotherapy for CD19+CD22+ Leukemia

Who this might be right for
LeukemiaLymphoma
Seattle Children's Hospital 78
Very early researchLooking for participantsNCT06279923
What this trial is testing

CD19-BAFF CAR-T Cells Therapy for Patients With Autoimmune Diseases

Who this might be right for
Autoimmune Diseases
Zhejiang University 45
Testing effectiveness (Phase 2)Looking for participantsNCT06081478
What this trial is testing

CD19/CD22 Bispecific CAR-T Cell Therapy for Relapsed/Refractory B-cell Lymphoma or Acute Lymphoblastic Leukemia

Who this might be right for
B-cell Acute Lymphoblastic LeukemiaB-cell LymphomaDiffuse Large B Cell Lymphoma
Beijing Tongren Hospital 100
Early research (Phase 1)WithdrawnNCT06752876
What this trial is testing

CRISPR-Edited Allogeneic Anti-CD19 CAR-T Cell Therapy, in Patients With Refractory Systemic Lupus Erythematosus (GALLOP)

Who this might be right for
Systemic Lupus ErythematosusLupusLupus Erythematosus+1 more
Caribou Biosciences, Inc.
Early research (Phase 1)Active Not RecruitingNCT03241940
What this trial is testing

Study of CD19/CD22 Chimeric Antigen Receptor T Cells in Children & Young Adults w/ Recurrent or Refractory B Cell Malignancies

Who this might be right for
B Acute Lymphoblastic LeukemiaCD19 PositiveMinimal Residual Disease+4 more
Stanford University 33
Very early researchLooking for participantsNCT06793241
What this trial is testing

Donor Derived CD19 CAR-T Cells in the Treatment of R/R B-cell Acute Lymphoblastic Leukemia

Who this might be right for
B-cell Acute Lymphoblastic Leukemia
Zhejiang University 15
Early research (Phase 1)UnknownNCT03086954
What this trial is testing

Study Evaluating the Efficacy and Safety With CAR-T Immunotherapy for CD19 Positive Lymphoma

Who this might be right for
Lymphoma
Sinobioway Cell Therapy Co., Ltd. 24
Testing effectiveness (Phase 2)Not Yet RecruitingNCT05091541
What this trial is testing

CT120 in Patient With Relapsed/Refractory B-cell Non-Hodgkin's Lymphoma

Who this might be right for
B-cell Non-Hodgkin's Lymphoma
Nanjing IASO Biotechnology Co., Ltd. 125
Testing effectiveness (Phase 2)Looking for participantsNCT05850234
What this trial is testing

AZD0120 in Relapsed/Refractory Multiple Myeloma (DURGA-1)

Who this might be right for
Relapsed/Refractory Multiple Myeloma
AstraZeneca 232
Not applicableStudy completedNCT03811457
What this trial is testing

Immunotherapy With CD19 CAR T-cells in Patients With Relapsed or Refractory CD19+ Leukemia and Lymphoma

Who this might be right for
Lymphoma Leukemia
UWELL Biopharma 9
Testing effectiveness (Phase 2)UnknownNCT03468153
What this trial is testing

Dual Specificity CD19 and CD22 CAR-T Cell Immunotherapy for CD19+CD22+ Relapsed and Refractory Lymphoma

Who this might be right for
Lymphoma
Ruijin Hospital 10
Very early researchNot Yet RecruitingNCT07277504
What this trial is testing

Autologous Bedside CD19 CAR T-cell Therapy for B-ALL

Who this might be right for
B-Cell Acute Lymphoblastic Leukemia, Adult
The General Hospital of Western Theater Command 50
Early research (Phase 1)Looking for participantsNCT07078929
What this trial is testing

Clinical Trial of CMD63 Chimeric Antigen Receptor T-cell (CAR T-cell) in Children With Acute Lymphoblastic Leukemia (ALL)

Who this might be right for
Relapse B Acute Lymphoblastic LeukemiaRefactory Childhood Acute Lymphoblastic Leukemia
Chulalongkorn University 16
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07503353
What this trial is testing

T-cell Expressing a Novel CD19 Chimeric-Antigen Receptor (SHB-02-CD19) in Patients With CD19-expressing B-cell Malignancies

Who this might be right for
B Cell MalignanciesAcute Lymphobkastic LeukemiaNon-Hodgekin Lymphoma (NHL-both Follicular & Diffuse Large Cell)
Sheba Medical Center 50
Next Page